32,253 Shares in Genomic Health, Inc. (GHDX) Purchased by Dupont Capital Management Corp

Dupont Capital Management Corp bought a new position in shares of Genomic Health, Inc. (NASDAQ:GHDX) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 32,253 shares of the medical research company’s stock, valued at approximately $1,103,000. Dupont Capital Management Corp owned approximately 0.09% of Genomic Health at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Cubist Systematic Strategies LLC bought a new stake in Genomic Health in the 3rd quarter worth about $138,000. Legal & General Group Plc grew its position in Genomic Health by 11.4% in the 2nd quarter. Legal & General Group Plc now owns 6,932 shares of the medical research company’s stock worth $226,000 after purchasing an additional 710 shares in the last quarter. Jane Street Group LLC bought a new stake in Genomic Health in the 3rd quarter worth about $227,000. Parametric Portfolio Associates LLC grew its position in Genomic Health by 5.8% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 8,051 shares of the medical research company’s stock worth $262,000 after purchasing an additional 441 shares in the last quarter. Finally, Voya Investment Management LLC grew its position in Genomic Health by 18.5% in the 2nd quarter. Voya Investment Management LLC now owns 8,622 shares of the medical research company’s stock worth $281,000 after purchasing an additional 1,344 shares in the last quarter. 89.81% of the stock is owned by institutional investors.

A number of brokerages have issued reports on GHDX. ValuEngine downgraded shares of Genomic Health from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. BidaskClub raised shares of Genomic Health from a “sell” rating to a “hold” rating in a research report on Tuesday, December 19th. William Blair downgraded shares of Genomic Health from an “outperform” rating to a “market perform” rating in a research report on Wednesday, December 20th. Zacks Investment Research raised shares of Genomic Health from a “sell” rating to a “hold” rating in a research report on Tuesday. Finally, Jefferies Group reaffirmed a “hold” rating and issued a $34.00 price objective on shares of Genomic Health in a research report on Friday, October 20th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the stock. Genomic Health has an average rating of “Hold” and an average target price of $32.33.

Genomic Health, Inc. (NASDAQ GHDX) traded down $0.23 on Thursday, reaching $32.72. 165,200 shares of the company’s stock were exchanged, compared to its average volume of 169,511. The stock has a market capitalization of $1,146.17, a PE ratio of -272.67 and a beta of 0.59. Genomic Health, Inc. has a 52-week low of $26.54 and a 52-week high of $37.50.

In related news, insider Phillip G. Febbo sold 5,334 shares of the company’s stock in a transaction that occurred on Tuesday, December 19th. The shares were sold at an average price of $36.99, for a total transaction of $197,304.66. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Laura Leber sold 21,000 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $33.29, for a total transaction of $699,090.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 69,338 shares of company stock worth $2,305,951. Corporate insiders own 46.20% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/15/dupont-capital-management-corp-invests-1-10-million-in-genomic-health-inc-ghdx-stock.html.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply